Fig 1: SPARC levels in serum and PBMC from LIHC. (A) Human protein atlas (HPA) database showed the SPARC expression profile in blood. (B, C) Differential SPARC mRNA expression in PBMC between LIHC and normal controls in GSE49515 and GSE58208 datasets. (D) Serum SPARC protein levels in LIHC and healthy controls (HC). (E) SPARC mRNA expression levels in PBMC from our sample in this study.
Fig 2: SPARC-associated genes and pathway enrichment in LIHC. (A) Heatmaps showing top 50 genes positively correlated (left) and top 50 genes negatively correlated with SPARC in LIHC (right). (B) Enriched KEGG pathways of SPARC-associated genes. (C–E) Enriched GO terms of SPARC-associated genes.
Fig 3: Endogenous SPARC overexpression promote liver cancer cells proliferation and tumor growth. (A) qRT-PCR showed the higher SPARC expression level in HepG2 SPARC . (B) SPARC overexpression promotes liver cancer cell proliferation. (C) FCM showed the effects of SPARC overexpression on cell cycle. (D) FCM showed the effects of SPARC overexpression on cell apoptosis. (E) SPARC overexpression promotes tumor growth in vivo.
Fig 4: SPARC mRNA expression in LIHC tissues and normal controls. (A) Differential SPARC mRNA expression between the LIHC and normal live tissues in the GEPIA2 database. (B) Differential SPARC mRNA expression between the LIHC and normal controls in the UALCAN database. (C–E) Differential SPARC expression between the LIHC tissues and non-tumor tissues in GSE121248, GSE14520, and GSE14323 datasets. (F, G) Boxplot of SPARC expression based on the tumor stage and grade. (H) Boxplot of SPARC promoter methylation level. (I) IHC analysis of LIHC tissue microarray.
Supplier Page from RayBiotech for Human SPARC (Osteonectin) ELISA